Commodore Capital LP Sells 900,000 Shares of Tyra Biosciences, Inc. $TYRA

Commodore Capital LP trimmed its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 26.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 2,475,000 shares of the company’s stock after selling 900,000 shares during the period. Tyra Biosciences comprises approximately 5.5% of Commodore Capital LP’s holdings, making the stock its 6th largest holding. Commodore Capital LP’s holdings in Tyra Biosciences were worth $94,792,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after acquiring an additional 534 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Tyra Biosciences by 2.0% in the fourth quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock valued at $753,000 after acquiring an additional 562 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Tyra Biosciences by 5.0% in the fourth quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock valued at $404,000 after acquiring an additional 725 shares during the last quarter. Virtus Investment Advisers LLC increased its position in Tyra Biosciences by 6.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock worth $309,000 after purchasing an additional 741 shares during the period. Finally, Hilton Head Capital Partners LLC acquired a new stake in Tyra Biosciences in the first quarter worth about $30,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Tyra Biosciences in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. Guggenheim initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price target for the company. JonesTrading assumed coverage on shares of Tyra Biosciences in a research note on Wednesday, June 17th. They set a “buy” rating and a $56.00 price target for the company. Finally, Wolfe Research assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $30.63 on Monday. Tyra Biosciences, Inc. has a 1-year low of $9.96 and a 1-year high of $40.65. The business’s 50-day moving average price is $30.68 and its two-hundred day moving average price is $32.60. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -14.05 and a beta of 0.76.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Sell-side analysts predict that Tyra Biosciences, Inc. will post -2.68 earnings per share for the current year.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.